Navigation Links
Scripps Florida scientists awarded $8.4 million grant to develop new anti-smoking treatments
Date:5/14/2012

JUPITER, FL, May 14, 2012 Scientists from the Florida campus of The Scripps Research Institute has been awarded an $8.4 million grant from the National Institute on Drug Abuse of the National Institutes of Health (NIH) to develop new compounds to help prevent relapse in smokers who are kicking the habit.

The new five-year NIH award is a program project grant, which is designed to support an institutionally based research program with a well-defined research focus that requires several interrelated subprojects as part of the overall study.

Paul Kenny, a Scripps Research associate professor, is the program director and principal investigator for the study.

"This really is a broad-based, multi-disciplinary team effort," Kenny said. "We've assembled a team of first-class scientists at Scripps Florida with all the experience necessary to develop novel therapeutics for the treatment of tobacco abuse."

Others involved in the study are Michael Cameron, Theodore Kamenecka, and Patricia McDonald of The Translational Research Institute on the Scripps Florida campus.

Tobacco smoking is a global scourge, killing more than 5 million people each year worldwide, according to the World Health Organization. It is estimated that if current trends continue, by 2020 smoking will become the largest single health problem worldwide. The World Bank estimates that in high-income countries, smoking-related healthcare accounts for between 6 and 15 percent of all healthcare costs, some $160 billion annually.

Nicotine addiction is notoriously hard to break. Even with the most effective smoking-cessation agents available, more than 80 percent of smokers who quit or attempt to quit will relapse.

To combat these dismal statistics, the study is focused on an entirely new mechanism to help smokers break the habit.

That mechanism is a receptor for a specific neuropeptide (short chain of amino acids found in nerve tissue) that, when blocked, significantly decreases the desire for nicotine in animal models.

The neuropeptide, known as hypocretin-1 or orexin A, initiates a key signaling cascade that maintains tobacco addiction in human smokers. In a 2008 study in the Proceedings of the National Academy of Sciences, Kenny and colleagues showed that blocking hypocretin-1 receptors not only decreased nicotine use in animal models, but also abolished the stimulatory effects of nicotine on brain reward circuitries. These results demonstrated that hypocretin-1 plays a major role in driving the desire for more nicotine.

These findings also highlighted the importance of hypocretin-1 receptors in a region of the brain called the insula, a walnut size part of the frontal lobe. While all mammals have insula regions that sense the body's internal physiological state and direct responses to maintain homeostasis, this region has also been implicated in cravings. In one study, it was reported that smokers who sustained damage to the insula lost the desire to smoke, an insight that revealed the insula as key for sustaining the tobacco habit in smokers.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert  

Related biology news :

1. Plastic trash altering ocean habitats, Scripps study shows
2. Scripps Florida scientists identify neurotranmitters that lead to forgetting
3. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
4. Scripps research scientists find anticonvulsant drug helps marijuana smokers kick the habit
5. Scientist wins $3 million renewal of one of longest-running NIH grants to Scripps Research
6. Scripps Research Institute scientists develop antidote for cocaine overdose
7. Scripps Research Institute Professor Gerald F. Joyce elected to American Academy of Arts & Sciences
8. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
9. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
10. Scripps Florida scientists awarded $3 million to develop new, more effective pain treatments
11. Scripps Florida team awarded nearly $1.5 million to develop potent new HIV inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Florida scientists awarded $8.4 million grant to develop new anti-smoking treatments
(Date:2/8/2017)... BEDFORD, Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... services, today reported financial results for its quarter and year ... fourth quarter of 2016 was $3.9 million compared to $6.9 ... the fourth quarter of 2016 was $0.6 million compared to ... in the fourth quarter of 2016 was $0.5 million, or ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... 24, 2017 Symic Bio, a biopharmaceutical company ... category of therapeutics, announced today the completion of enrollment ... artery disease. The trial will evaluate the safety and ... the reduction of restenosis following angioplasty. ... for SB-030," said Nathan Bachtell , M.D., Chief ...
(Date:2/24/2017)... Feb. 24, 2017 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its unaudited financial results for the third quarter ... December 31, 2016. Third Quarter of Fiscal ... quarter of fiscal 2017 increased by 18.6% to RMB200.9 ...
(Date:2/24/2017)... Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a ... its financial results for the fourth quarter and fiscal year ... Total sales in the fourth quarter ... by 13.6% in USD terms to $77.6 million from $68.3 ... Gross profit increased by 13.3% to $46.8 million from $41.3 ...
(Date:2/24/2017)...  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company ... Opinion Leader event to highlight new clinical data that ... at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and the ... held in-person and via live webcast on Tuesday, February ... at the Lotte New York Palace Hotel in ...
Breaking Biology Technology: